Water in the chest – new findings on pleural effusion

February 28, 2018, Helmholtz Association of German Research Centres
Water in the chest – new findings on pleural effusion
The analysis shows a specific reaction of KRAS mutant cells to the messenger IL-1b in red. Other messengers had no effect (blue). Credit: Helmholtz Zentrum München

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the German Center for Lung Research (DZL), have discovered a novel mechanism that causes this to happen. Their study, published in Nature Communications, now refines the mechanistic picture.

Malignant pulmonary effusion (MPE) frequently occurs in patients with metastatic breast or lung cancer. It involves a build-up of excess fluid in the pleural cavity, the area between the lungs and the , with accompanying malignant cells. The lung is surrounded by fluid, which can cause shortness of breath and chest pain, for example, and may even prove fatal.

"The cause is still not fully understood, which makes the search for suitable therapies more difficult," explains Professor Georgios Stathopoulos, research group leader at the Institute of Lung Biology (ILBD) and the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum München. "However, we've now made significant progress in that direction."

In their recent work, the team built on findings which they had also published in Nature Communications in May 2017. "At the time, we were able to show that pleural effusion is triggered by cancer cells with a malignant mutation in the KRAS gene," says Dr. Antonia Marazioti, lead author of the paper and scientist at the Molecular Respiratory Carcinogenesis Research Group in the medical department of the University of Patras, which is also led by Georgios Stathopoulos in close connection to his ILBD/CPC work at the Helmholtz Zentrum München.

Credit: Helmholtz Zentrum München

The authors have now been able to expand on this knowledge. "Our experiments show that inflammatory messengers of the immune system − notably interleukin-1β − activate a signaling pathway in mutated cancer cells, which in the long term can lead to pleural effusion," Stathopoulos explains. The molecule IKKα plays a key role in the signaling pathway in that it, in turn, releases other messengers (CXCL1), resulting in a strong inflammatory response (see illustration). "Consequently, those cells migrate to the via the spleen, where they cause effusion," explains the lung expert.

Double-pronged inhibition is better

To determine whether the findings might prove relevant to future treatment strategies, the researchers suppressed the newly discovered signaling pathway in the experimental model from two sides. In their double-pronged approach, they used both an inhibitor of KRAS and an inhibitor of IKKα. "In fact, this dual strategy significantly reduced both the incidence and the progression of MPE," Stathopoulos reports. Resistance to a single treatment was also reduced.

"Nearly two thirds of all MPEs are the result of . Given the large number of people who still smoke, appropriate therapies are urgently needed," Georgios Stathopoulos says. "Our findings suggest that drugs could become a therapeutic option for suppressing the mechanism we've discovered. We plan to investigate this line of enquiry in greater depth in the future and to further confirm the results in the translational approach with in collaboration with the Asklepiosklinik in Gauting."

Explore further: How cancer cells flood the lung

More information: Antonia Marazioti et al. Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion, Nature Communications (2018). DOI: 10.1038/s41467-018-03051-z

Related Stories

How cancer cells flood the lung

May 19, 2017
Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the ...

Unique lipid profile could help diagnose and treat lung cancer

September 8, 2017
The lipid contents of a fluid that surrounds the lungs in some diseases contains specific fats that could be used as a biomarker to distinguish people with and without lung cancer. It can also identify a subtype of the cancer ...

Study examines treatments for relieving breathing difficulties among patients with lung effusions

May 20, 2012
Helen E. Davies, M.D., of the University Hospital of Wales, Cardiff, and colleagues compared the effectiveness of treatments to relieve breathing difficulties among patients with malignant pleural effusion (presence of fluid ...

Lymph node stage may have clinical significance among NSCLC patients with stage IV M1a

August 24, 2016
Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.

Effectiveness of pain medications for patients receiving treatment for lung condition

December 22, 2015
Use of NSAIDs vs opiates resulted in no significant difference in measures of pain but was associated with more rescue medication (additional medicine needed due to uncontrolled pain) among patients with malignant pleural ...

How the lungs of premature babies can undergo damage

September 29, 2017
Premature babies that need ventilation to support their breathing often suffer from a condition known as bronchopulmonary dysplasia. Researchers at the Helmholtz Zentrum München, partner in the German Center for Lung Research ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.